Skip to main content
Pharos iBio Co., Ltd. logo

Pharos iBio Co., Ltd. — Investor Relations & Filings

Ticker · 388870 ISIN · KR7388870008 KO Professional, scientific and technical activities
Open in API
Filings indexed 83 across all filing types
Latest filing 2024-02-14 Earnings Release
Country KR South Korea
Listing KO 388870

About Pharos iBio Co., Ltd.

https://www.pharosibio.com/en/

Pharos iBio is a clinical-stage biotechnology company that specializes in drug discovery and development. The company leverages a proprietary platform based on artificial intelligence (AI) and big data to identify and create novel therapeutic candidates. Its primary focus is on developing treatments for rare and refractory diseases, with a significant emphasis on oncology. The development pipeline includes assets that are progressing through clinical trials, such as a therapy for acute myeloid leukemia.

Recent filings

Filing Released Lang Actions
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (Pharos iBio) announcing a significant change in financial structure (revenue/profit fluctuation of 30% or more). This is a standard regulatory disclosure requirement in the Korean market (DART system) for listed companies to report material financial changes. Since it is a specific regulatory disclosure of financial results rather than a full annual report, a conference call transcript, or a simple report announcement, it falls under the 'Regulatory Filings' category. FY 2023
2024-02-14 Korean
기타경영사항(자율공시)((특허권 취득))
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from Pharos iBio regarding the acquisition of a patent in Japan for a specific chemical compound used in ovarian cancer treatment. It is categorized as a 'voluntary disclosure' (자율공시) under Korean regulatory standards. Since it does not fit into specific categories like M&A, financial reports, or director dealings, and is a standard regulatory announcement of a corporate event, it falls under the RNS (Regulatory Filings) category.
2023-12-18 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a short regulatory announcement regarding the setting of a record date for the purpose of holding an upcoming Annual General Meeting (AGM). It does not contain the full AGM materials or proxy statements, but rather serves as a formal notice of the record date for shareholder rights. Given the nature of the announcement as a regulatory disclosure regarding meeting preparation, it fits best under the RNS category as a general regulatory filing.
2023-12-15 Korean
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for the company 'Pharos iBio Co., Ltd.' covering the period from January 1, 2023, to September 30, 2023. It contains detailed financial information, business operations, management discussions, and corporate governance details, which are characteristic of a formal quarterly financial report filed with regulatory bodies (Financial Services Commission and Korea Exchange). 9M 2023
2023-11-14 Korean
타법인주식및출자증권취득결정(자율공시)
M&A Activity Classification · 1% confidence The document is a regulatory filing from a Korean company (Pharos iBio) regarding the acquisition of shares in another corporation (Pharos Therapeutics INC.). This type of disclosure is a standard corporate event announcement required by the Korea Exchange (KRX) for material business decisions, specifically categorized as a 'Major Business Decision' or 'Autonomous Disclosure' (자율공시). Since it details a specific capital investment/acquisition of a subsidiary, it falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A (which usually implies mergers or takeovers of external entities) or Share Issue (which is about the company's own capital structure).
2023-10-30 Korean
기타경영사항(자율공시)(특허권 취득)
Regulatory Filings Classification · 1% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent (특허권 취득) by Pharos iBio. It details the patent name, the nature of the technology (protein kinase inhibitor), the registration country (Brazil), and the strategic utilization plan. Since this is a regulatory announcement of a specific corporate event that does not fall into financial reporting, dividend announcements, or management changes, it is classified as a general regulatory filing.
2023-10-10 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.